Oral Delivery of Large Molecules
Oral Delivery of Large Molecules
Home
About Us
Company Profile
Strategy
Management Team
Board of Directors
Technology
Oral Drug Delivery
Parathyroid Hormone
Supportive Publications
Pipeline
Progress Summary
Hypoparathyroidism
Osteoporosis
Bone Healing
News and Events
News
Events
Investors
Oral Delivery of Large Molecules
Sitemap
Main Menu
Home
About Us
Strategy
Management Team
Dr. Phillip Schwartz President of R&D and Executive Vice President
Dr. Hillel Galitzer – COO
Dr. Arthur Santora - CMO
Dr. Roger Garceau- Chief Development Advisor
Dana Yaacov-Garbeli, CPA, - Israel CFO.
Ramesh Ratan US CFO
Dr. Spiros Jamas - CEO
Board of Directors
Mr. Ron Mayron
Dr. Roger Garceau
Mr. Gerald Lieberman - Chairman of the Board
Mr. Yonatan Malca
Dr. Phillip Schwartz
Faith L. Charles
Miranda J. Toledano
Mr. Gerald M. Ostrov
Dr. Spiros Jamas -CEO
Technology
Parathyroid Hormone
Pipeline
Hypoparathyroidism
Overview
Market
Current Status
Osteoporosis
Overview
Market
Current Status
Bone Healing
Overview
Market
Current Status
Events
ASBMR 2012
ASBMR 2013
ASBMR 2014
ASBMR 2015
ASBMR 2016
ASBMR 2017
ASBMR 2018
ASBMR 2019
Article in the Journal of Bone and Mineral Research
AlphaStreet interview with CEO Spiros Jamas
ASMBR 2021
Oral Presentation of 6-Month BMD data at ASBMR
Study of Oral Delivery Technology Platform for Biological Drugs
bottom Menu
Sitemap